Orthopaedics
Physician-led assessment of joint, cartilage, tendon, ligament and degenerative musculoskeletal conditions.
Review the Orthopaedics Program →
CELLMEX Clinical Programs
Individualised regenerative medicine within structured clinical care.
CELLMEX clinical programmes combine physician evaluation, diagnosis-specific review, conventional medical care, rehabilitation, biological treatment assessment and structured follow-up. No regenerative therapy is automatically suitable for every patient or medical condition.
Clinical Programme Overview
A clinical programme is more than a biological procedure
A CELLMEX clinical programme begins with medical evaluation—not with automatic selection of a stem cell, exosome or secretome treatment.
The treating physician reviews the diagnosis, disease severity, previous therapies, current medication, laboratory studies, imaging, functional status and relevant contraindications.
A regenerative intervention may be considered only when it has a medically supportable rationale and when the patient understands the limitations, alternatives, potential risks and uncertainty of benefit.
Depending on the programme, care may also involve conventional medication, physical rehabilitation, nutritional support, specialist consultation, metabolic optimisation or referral for standard hospital treatment.
Clinical Programme Directory
Explore our principal clinical programme areas
Each programme requires diagnosis-specific medical review. Listing a condition does not represent a promise of treatment eligibility or clinical benefit.
Sports Medicine
Evaluation of sports injuries, overuse disorders, tissue recovery, rehabilitation and return-to- activity planning.
Review the Sports Medicine Program →Neurology
Multidisciplinary review of selected neurological conditions, including dedicated evaluation pathways for MS and ALS enquiries.
Review the Neurology Program →Autoimmune Disorders
Specialist evaluation of selected immune-mediated and chronic inflammatory conditions.
Review the Autoimmune Program →Diabetes
Integrated review of diabetes control, complications, vascular health, tissue repair and investigational regenerative approaches.
Review the Diabetes Program →Cosmetic & Aesthetic Medicine
Physician-supervised programmes addressing skin quality, texture, appearance and selected restorative procedures.
Review the Aesthetic Program →Healthy Ageing
Medical evaluation focused on function, mobility, metabolic health, recovery, sleep and age-related health risks.
Review the Healthy Ageing Program →
Treatment and Technology Platforms
Biological technologies considered within CELLMEX programmes
Availability and suitability depend on product identity, the proposed clinical use, physician review, supporting evidence and applicable requirements.
Mesenchymal Stromal Cells
MSC preparations may be evaluated for selected musculoskeletal, inflammatory or other regenerative applications.
- Source and manufacturing review
- Cell count and viability
- Route-of-administration assessment
- Condition-specific medical rationale
Extracellular Vesicles and Exosome-Related Preparations
Small extracellular-vesicle or exosome-related preparations may be discussed only after adequate review of their source, processing, characterisation and intended use.
- Product identity and terminology
- Isolation or enrichment method
- Particle and marker information
- Safety and evidence limitations
MSC Secretome and Conditioned Media
Secretome-associated preparations may contain soluble and vesicular products released by cultured cells. Their composition varies with the source cells and manufacturing process.
- Conditioned-media formulation
- Secreted growth factors and proteins
- Vesicular and soluble fractions
- Exosome-depleted preparations
Tissue-Directed and Differentiated MSCs
Tissue-directed cell systems involve controlled laboratory conditions intended to influence cellular phenotype or lineage-associated characteristics.
- Phenotype verification
- Functional laboratory assessment
- Tissue-specific development
- Separate clinical and regulatory review
Immune-Cell Technologies
Selected immune-cell technologies may be evaluated in research or specialist clinical-development settings.
- Cell identity and purity
- Activation or expansion methods
- Functional assessment
- Disease-specific medical oversight
Supportive and Conventional Therapies
Regenerative programmes may require conventional care rather than, or in addition to, a biological intervention.
- Physical rehabilitation
- Medication review
- Nutritional and metabolic care
- Specialist referral
Orthopaedics Clinical Program
Joint, cartilage, tendon and musculoskeletal care
Conditions commonly evaluated
- Knee, hip, shoulder and ankle osteoarthritis
- Selected cartilage injuries
- Tendinopathy and partial tendon injuries
- Ligament and soft-tissue injuries
- Chronic musculoskeletal pain with a defined diagnosis
- Delayed functional recovery after injury
Treatment considerations
Treatment planning may include rehabilitation, load management, medication review, standard orthopaedic procedures or physician-supervised biological intervention.
Severe structural disease, mechanical instability or advanced joint destruction may require conventional surgical evaluation rather than regenerative treatment.
Information usually required
- Orthopaedic diagnosis
- Recent X-rays, MRI or ultrasound
- Previous injections or surgery
- Current pain and functional limitations
- Rehabilitation history
Sports Medicine Clinical Program
Injury assessment, recovery and return-to-activity planning
Integrated sports medicine approach
Biological intervention, when considered, should be one component of a broader recovery programme that addresses biomechanics, strength, flexibility, conditioning and injury prevention.
Potential programme components
- Sports-medicine physician assessment
- Diagnostic imaging review
- Functional and biomechanical evaluation
- Rehabilitation programme
- Recovery-progress monitoring
- Return-to-activity criteria
Neurology Clinical Program
Specialist neurological review and supportive clinical planning
Neurological conditions require specialist diagnosis, realistic treatment objectives and continued coordination with the patient's neurologist.
Programme objectives
Depending on the condition, objectives may include maintaining function, managing symptoms, reducing preventable complications, supporting rehabilitation and reviewing investigational options without replacing established care.
Neurological enquiries considered individually
CELLMEX may receive enquiries involving neuroinflammatory, neurodegenerative, neuromuscular or acquired neurological conditions. Acceptance for evaluation does not confirm eligibility for a cellular or cell-derived intervention.
Special Neurology Section
Multiple Sclerosis and Amyotrophic Lateral Sclerosis
MS and ALS are medically distinct neurological conditions. They require separate diagnostic, therapeutic and research considerations and must not be grouped under a single standardised regenerative protocol.
Multiple Sclerosis Program
Multiple sclerosis is an immune-mediated disorder affecting the central nervous system. Evaluation should identify the MS subtype, disease activity, disability status, current disease-modifying therapy and history of relapses.
Programme review may include:
- Neurologist-confirmed diagnosis
- Relapsing or progressive disease classification
- MRI and neurological reports
- Current and previous disease-modifying treatments
- Mobility, fatigue and functional assessment
- Infection and immune-status review
- Rehabilitation and symptom-management planning
Certain stem-cell-related strategies studied in MS involve specialised haematopoietic stem-cell transplantation protocols. These are fundamentally different from routine MSC infusions or exosome-related procedures.
Important:
MS disease-modifying medication should not be
discontinued or delayed for an unproven
regenerative intervention without direction from
the treating neurologist.
ALS Clinical Evaluation Program
Amyotrophic lateral sclerosis is a progressive motor-neuron disease. Cellular and cell-derived approaches remain investigational and must not be represented as established cures.
Programme review may include:
- Neurologist-confirmed ALS diagnosis
- Symptom onset and progression history
- Respiratory function
- Swallowing and nutritional status
- Mobility and activities of daily living
- Current ALS medication
- Genetic information, where relevant
- Palliative and supportive-care requirements
The clinical priority remains coordinated neurological care, respiratory support, nutritional management, communication support, mobility assistance and established disease-modifying treatment where appropriate.
Important:
Acceptance of an ALS enquiry does not imply that
CELLMEX can reverse motor-neuron loss, stop disease
progression or restore lost neurological function.
Mandatory transparency for MS and ALS
CELLMEX should not publish language stating or implying that MSCs, exosomes, secretome products or other regenerative preparations cure MS or ALS. Any investigational proposal must be discussed separately from established neurological care and must include clear disclosure of uncertainty, limitations, alternatives and possible risks.
Autoimmune and Inflammatory Disorders Program
Individualised review of immune-mediated disease
Conditions reviewed individually
Enquiries may involve selected rheumatological, gastrointestinal, neurological or systemic immune-mediated conditions. The scientific evidence and appropriate standard of care differ substantially between diagnoses.
Clinical principles
- Continue appropriate specialist care
- Avoid abrupt immunosuppressive medication changes
- Screen for active or latent infection
- Review organ function and disease complications
- Define measurable clinical objectives
Diabetes Clinical Program
Metabolic control, complications and regenerative research
Standard diabetes care remains central
Regenerative therapies should not be presented as replacements for insulin, glucose monitoring, approved medication, nutritional care or management of cardiovascular and renal risk.
Potential research and supportive areas
- Chronic wound and tissue-repair support
- Diabetic-foot multidisciplinary evaluation
- Vascular and neuropathy assessment
- Metabolic optimisation before procedures
- Research into cellular and paracrine mechanisms
No insulin-discontinuation promises
A patient should never stop or reduce insulin solely because a regenerative procedure has been proposed or administered. Medication changes require appropriate clinical supervision and objective metabolic data.
Cosmetic & Aesthetic Medicine Program
Physician-supervised skin and restorative care
Treatment planning
Treatment may involve established aesthetic procedures, physician-guided skin care and carefully evaluated biological preparations.
The term “exosome” should not be used as a quality claim unless the preparation has been appropriately characterised.
Realistic expectations
Outcomes vary according to age, skin condition, sun exposure, smoking, metabolic health, treatment technique and the identity of the preparation used.
Healthy Ageing Program
Function, resilience and prevention—not reversal of ageing
Why “healthy ageing” is more accurate than “anti-ageing”
No treatment stops or reverses the biological ageing process. The clinical objective is to support health, function, independence and management of modifiable risk factors.
Programme components
- Medical and medication review
- Metabolic and laboratory assessment
- Strength, balance and mobility evaluation
- Nutritional planning
- Sleep and recovery review
- Specialist referral where required
Clinical Programme Pathway
From initial enquiry to structured follow-up
Initial Enquiry
The patient or referring physician identifies the diagnosis and reason for requesting evaluation.
Medical Records
Relevant reports, imaging, laboratory results, medication history and previous treatments are submitted.
Physician Review
A physician determines whether further consultation or additional testing is appropriate.
Clinical Evaluation
The patient undergoes diagnosis-specific assessment and review of risks, alternatives and objectives.
Treatment Plan
Eligible patients receive a written plan describing the proposed care, costs and follow-up.
Follow-Up
Safety, symptoms, function and continuing medical needs are assessed after treatment.
Eligibility and Safety
Clinical acceptance is based on individual review
Information considered
- Confirmed diagnosis
- Severity, progression and duration
- Previous and current treatment
- Laboratory and imaging findings
- Organ function and comorbidities
- Realistic clinical objectives
Factors that may delay or prevent treatment
- Active infection or uncontrolled illness
- Uncertain or incomplete diagnosis
- Severe procedural risk
- Inability to provide informed consent
- Unrealistic expectations
- Lack of an adequate scientific or medical rationale
Clinical Follow-Up
Care continues beyond the procedure
Immediate Monitoring
Observation for acute reactions, procedural complications and changes requiring medical review.
Early Safety Review
Assessment of pain, fever, swelling, infection, allergic symptoms or unexpected deterioration.
Functional Review
Programme-specific assessment of mobility, pain, fatigue, neurological function or quality of life.
Ongoing Medical Care
Coordination with referring physicians and continued standard care where clinically required.
Clinical Program FAQ
Frequently asked questions
Does CELLMEX treat every condition listed on this page?
No. The conditions listed represent programme areas for medical evaluation. Eligibility for a specific treatment depends on diagnosis, clinical condition, evidence, product availability and physician review.
Are MSCs used in every clinical programme?
No. Some patients may not require or qualify for an MSC-based intervention. The appropriate plan may involve standard care, rehabilitation, another biological platform or referral to a different specialist.
Does CELLMEX offer exosome therapy?
CELLMEX evaluates extracellular-vesicle and exosome-related technologies. Any proposed use must be based on the specific product's source, processing, characterisation, evidence and clinical context.
The term “exosome” alone does not establish product quality, purity, safety or clinical effectiveness.
Can CELLMEX cure Multiple Sclerosis?
CELLMEX should not represent any regenerative intervention as a cure for MS. Patients require specialist neurological assessment and should continue appropriate disease-modifying and supportive care.
Can CELLMEX cure ALS?
No curative claim should be made. Cellular and cell-derived approaches for ALS remain investigational. The clinical priority remains coordinated neurological, respiratory, nutritional, mobility and supportive care.
Can diabetes patients stop insulin after treatment?
No patient should stop or reduce insulin without medical direction. A regenerative procedure does not automatically replace insulin, glucose monitoring or established diabetes treatment.
How much does a clinical programme cost?
Cost depends on the programme, diagnosis, consultations, testing, treatment platform, number of procedures, rehabilitation and follow-up requirements.
Eligible patients should receive a written treatment plan and cost estimate before making a commitment.
Can international patients participate?
Yes. International patients may submit medical records for preliminary review before making travel arrangements.
Will CELLMEX communicate with my regular physician?
With appropriate patient authorisation, CELLMEX may communicate relevant clinical and follow-up information to the referring or local physician.
Important clinical qualification
The technologies described on this page do not have the same level of clinical evidence, regulatory status or medical acceptance for every condition.
Stem-cell, extracellular-vesicle, exosome, secretome, conditioned-media and immune-cell applications may be investigational. A patient's eligibility must be determined through individual medical review.
CELLMEX does not guarantee cures, reversal of disease, permanent tissue regeneration or a specific clinical outcome.
Do not delay established care
Patients should not discontinue prescribed medication, delay surgery, interrupt neurological treatment, abandon diabetes management or postpone emergency care while seeking a regenerative medicine evaluation.
Clinical Programme Enquiry
Request preliminary medical review
Provide a concise medical summary. Detailed records should be submitted only through the secure method supplied after initial review.
General Email
info@cellmex.comTelephone
+52 322 308 0021Location
Marina Vallarta
Puerto Vallarta, Jalisco
Mexico
Important
This form is not an emergency medical service.